Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains. 2023

Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.

In a range of human disorders such as multiple myeloma (MM), immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can lead to pathological aggregation and deposition of IgLCs in different tissues, which in turn leads to severe and potentially fatal organ damage. However, IgLCs can also be highly soluble and non-toxic. It is generally thought that the cause for this differential solubility behaviour is solely found within the IgLC amino acid sequences, and a variety of individual sequence-related biophysical properties (e.g. thermal stability, dimerisation) have been proposed in different studies as major determinants of the aggregation in vivo. Here, we investigate biophysical properties underlying IgLC amyloidogenicity. We introduce a novel and systematic workflow, Thermodynamic and Aggregation Fingerprinting (ThAgg-Fip), for detailed biophysical characterisation, and apply it to nine different MM patient-derived IgLCs. Our set of pathogenic IgLCs spans the entire range of values in those parameters previously proposed to define in vivo amyloidogenicity; however, none actually forms amyloid in patients. Even more surprisingly, we were able to show that all our IgLCs are able to form amyloid fibrils readily in vitro under the influence of proteolytic cleavage by co-purified cathepsins. We show that (I) in vivo aggregation behaviour is unlikely to be mechanistically linked to any single biophysical or biochemical parameter and (II) amyloidogenic potential is widespread in IgLC sequences and is not confined to those sequences that form amyloid fibrils in patients. Our findings suggest that protein sequence, environmental conditions and presence and action of proteases all determine the ability of light chains to form amyloid fibrils in patients.

UI MeSH Term Description Entries
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000682 Amyloid A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease. Amyloid Fibril,Amyloid Fibrils,Amyloid Substance,Fibril, Amyloid,Fibrils, Amyloid,Substance, Amyloid
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses

Related Publications

Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
January 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
January 1973, Cleveland Clinic quarterly,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
May 1982, Clinical chemistry,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
January 2017, Annals of clinical biochemistry,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
December 1980, Clinical and experimental immunology,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
August 2004, British journal of haematology,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
February 2005, British journal of haematology,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
June 2018, Clinical laboratory,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
January 2007, Haematologica,
Rebecca Sternke-Hoffmann, and Thomas Pauly, and Rasmus K Norrild, and Jan Hansen, and Florian Tucholski, and Magnus Haraldson Høie, and Paolo Marcatili, and Mathieu Dupré, and Magalie Duchateau, and Martial Rey, and Christian Malosse, and Sabine Metzger, and Amelie Boquoi, and Florian Platten, and Stefan U Egelhaaf, and Julia Chamot-Rooke, and Roland Fenk, and Luitgard Nagel-Steger, and Rainer Haas, and Alexander K Buell
July 1970, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!